Alpha Cognition Inc ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

NDAQ:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Mar 07, 2022 3:48pm

131 Views

Post# 34492260

$ACOG to present at Life Sciences Investor Forum (March 10)

Alpha Cognition ($ACOG.V $ACOGF) is in the green after the announcement that it will present at the Life Sciences Investor Forum on March 10th and 2:30pm.

Those who register for the conference will also have the ability to schedule a 1 on 1 meeting with $ACOG presenters.

$ACOG also

Sources: https://finance.yahoo.com/news/life-sciences-virtual-investor-conference-133500966.html

$ACOG @ 1.03

MC $62.726M

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season